Sullivan & Worcester and Hogan Lovells US advised Plus Therapeutics, while Sichenzia Ross Ference Carmel represented D. Boral Capital on the offering.Plus Therapeutics, Inc. (Nasdaq: PSTV),…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
